Calliditas Therapeutics AB (publ) logo

Calliditas Therapeutics AB (publ)NASDAQ: CALT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Sweden

IPO:

05 June 2020

Next earnings report:

11 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.08 B
-9%vs. 3y high
74%vs. sector
-vs. 3y high
-vs. sector
107.40
-9%vs. 3y high
100%vs. sector
-76%vs. 3y high
68%vs. sector

Price

regular market | Fri, 27 Sep 2024 13:30:00 GMT
$40.00(0.00%)

Dividend

No data over the past 3 years
$52.48 M$57.11 M
$52.48 M-$4.45 M

Analysts recommendations

Institutional Ownership

Included in screeners

No data

CALT Latest News

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
prnewswire.com03 September 2024 Sentiment: NEUTRAL

STOCKHOLM , Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg.

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
prnewswire.com03 September 2024 Sentiment: NEUTRAL

STOCKHOLM , Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (Nasdaq: CALT) ("Calliditas" or the "Company"), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of Calliditas has resolved, in accordance with a request from Asahi Kasei, to take certain corporate actions.

Calliditas Interim Report January to June 2024
prnewswire.com13 August 2024 Sentiment: POSITIVE

STOCKHOLM , Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.

STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALT
globenewswire.com27 July 2024 Sentiment: NEUTRAL

NEW YORK, July 27, 2024 (GLOBE NEWSWIRE) -- NEW YORK, July 27, 2024 / GlobeNewswire/-- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB (NASDAQ: CALT ), relating to a tender offer from Asahi Kasei Corporation. Under the terms of the offer, Asahi Kasei Corporation will acquire all the outstanding shares of Calliditas stock for SEK 0.04 in cash per ADS.

STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT
prnewswire.com26 July 2024 Sentiment: NEUTRAL

NEW YORK , July 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB (NASDAQ: CALT), relating to a tender offer from Asahi Kasei Corporation.

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
prnewswire.com26 July 2024 Sentiment: POSITIVE

STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM trial met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus placebo. The trial evaluated setanaxib, a NOX enzyme inhibitor, in patients with primary biliary cholangitis (PBC) and elevated liver stiffness.

Launch of Phase 3 clinical trial with Nefecon in Japan
prnewswire.com04 July 2024 Sentiment: POSITIVE

STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy (IgAN).

Calliditas provides setanaxib patent update
prnewswire.com18 June 2024 Sentiment: POSITIVE

STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for application no. 16/760,910 entitled "Use of NOX Inhibitors for Treatment of Cancer.

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
prnewswire.com17 June 2024 Sentiment: POSITIVE

STOCKHOLM , June 17, 2024 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 17 June 2024, in Stockholm. Adoption of income statement and balance sheet for the financial year 2023 and discharge from liability The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB – CALT
globenewswire.com05 June 2024 Sentiment: NEGATIVE

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB ( NASDA Q: CALT ), relating to a tender offer from Asahi Kasei Corporation. Under the terms of the offer, Asahi Kasei Corporation will acquire all the outstanding shares of Calliditas stock for SEK 0.04 in cash per ADS.

  • 1(current)
  • 2

What type of business is Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.

What sector is Calliditas Therapeutics AB (publ) in?

Calliditas Therapeutics AB (publ) is in the Healthcare sector

What industry is Calliditas Therapeutics AB (publ) in?

Calliditas Therapeutics AB (publ) is in the Biotechnology industry

What country is Calliditas Therapeutics AB (publ) from?

Calliditas Therapeutics AB (publ) is headquartered in Sweden

When did Calliditas Therapeutics AB (publ) go public?

Calliditas Therapeutics AB (publ) initial public offering (IPO) was on 05 June 2020

What is Calliditas Therapeutics AB (publ) website?

https://www.calliditas.se

Is Calliditas Therapeutics AB (publ) in the S&P 500?

No, Calliditas Therapeutics AB (publ) is not included in the S&P 500 index

Is Calliditas Therapeutics AB (publ) in the NASDAQ 100?

No, Calliditas Therapeutics AB (publ) is not included in the NASDAQ 100 index

Is Calliditas Therapeutics AB (publ) in the Dow Jones?

No, Calliditas Therapeutics AB (publ) is not included in the Dow Jones index

When was Calliditas Therapeutics AB (publ) the previous earnings report?

No data

When does Calliditas Therapeutics AB (publ) earnings report?

The next expected earnings date for Calliditas Therapeutics AB (publ) is 11 November 2024